Genmab A/S

435 articles about Genmab A/S

• Genmab A/S Announces Year End 2005 Financial Results

  2/16/2006

• Genmab A/S Licenses Angiogenesis Targets From Bionomics Limited

  2/14/2006

• Genmab A/S's HuMax-EGFr Awarded Fast Track Status From FDA

  1/3/2006

• Genmab A/S Appoints Annarie Lyles As Head Of Business Development

  1/3/2006

• Roche Files IND For Genmab (GNMSF.PK) Antibody

  12/13/2005

• Genmab A/S Release: HuMax-CD20 Induces Rapid Responses In Relapsed CLL Patients

  12/13/2005

• Genmab A/S Release: HuMax-CD38 Effective In Preclinical Studies

  12/12/2005

• Genmab A/S Announces Responses With HuMax-CD4(TM) In Non-Cutaneous T-Cell Lymphoma

  12/12/2005

• Genmab A/S Announces Data On All Evaluable Patients In HuMax(R)-CD20 NHL Phase I/II Study

  12/1/2005

• Genmab A/S Announces Results For The First Nine Months Of 2005

  11/8/2005

• Genmab A/S Receives Patent For HuMax-HepC

  11/3/2005

• The Day In Review: Biotech Rises Again

  5/18/2005

• Genmab Licenses HuMax-TAC To Serono In Deal Worth Up To $40M

  5/4/2005

• James D. Watson Helix Awards Honor Biotech's Top Performers

  2/24/2005

• Genmab A/S's HuMax-CD4 Receives EU Orphan Drug Designation

  5/26/2004